Tag: Nasdaq:CYCC

January 28, 2019

Cyclacel Ready for More Clinical Data After Positive 2018

Spiro Rombotis and Paul McBarron of Cyclacel Pharmaceuticals discuss the company's pipeline, indications, clinical data and more.
October 21, 2018

5 Top Weekly NASDAQ Biotech Stocks: MannKind Leads the Pack

MannKind, Sierra Oncology, Eiger BioPharmaceuticals, Aevi Genomic Medicine and KalVista Pharmaceuticals were last week's top gainers on the NASDAQ Biotechnology...
October 7, 2018

5 Top Weekly NASDAQ Biotech Stocks: vTv Leads with 374 Percent

vTv Therapeutics, Trevena, Cyclacel Pharmaceuticals, Paratek Pharmaceuticals and Avadel Pharmaceuticals were last week's top gainers on the NASDAQ Biotechnology Index.
September 10, 2018

Cyclacel Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Sapacitabine With Olaparib in BRCA Mutant Breast Cancer

Cyclacel Pharmaceuticals (Nasdaq:CYCC, Nasdaq:CYCCP) a biopharmaceutical company developing innovative medicines based on cancer biology, announced the initiation of a Phase...